LIMA--Prime Minister Shigeru Ishiba held his first meeting with Chinese President Xi Jinping here on the sidelines of the Asia-Pacific Economic Cooperation summit. “We were able to have an ...

Get full unrestricted access to all ch-aviation features and data including worldwide airline fleets, schedules and route network with drilldowns available at your fingertips on every screen - updated ...

👋 Welcome, this is THEO! THEOplayer delivers top-notch video playback cross-platform, whether your viewers are streaming on desktop, mobile, set-top boxes, smart TVs or gaming consoles. Leading media ...

THEO-260 is a mechanistically novel oncolytic immunotherapy developed to tackle the stromal rich tumour microenvironment (TME) evident in advanced ovarian cancer and other solid tumours.

For information on reporting security vulnerabilities in Jitsi Meet, see SECURITY.md. If you are looking to contribute to Jitsi Meet, first of all, thank you! Please see our guidelines for ...

Theolytics CSO and Co-Founder Margaret Duffy PhD, added“Enrolling the first patient into our Phase I/IIa trial for THEO-260 marks a major milestone for Theolytics. As a team, we seek to deliver ...

The Phase I/IIa trial is designed to investigate the safety and tolerability of THEO-260 administered via intravenous delivery and determine the recommended Phase II dose. Oxford, UK November 19, 2024 ...

open-label first-in-human trial (OCTOPOD - NCT06618235) of THEO-260 in patients with advanced-stage platinum-resistant ovarian cancer (PROC). Ovarian Cancer is one of the leading causes of cancer ...

Theo Burman is a Newsweek Live News Reporter based in London, U.K. His focus is on U.S. politics and international news, as well as the impact of digital culture on elections. He has covered ...